Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | APBB1 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
mRNA | DSTN | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
mRNA | TNFRSF1A | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
mRNA | IL3RA | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
mRNA | CTD-2369P2.12 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
mRNA | CBR1 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
mRNA | RASGRP2 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.001 |
mRNA | L3MBTL2 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
mRNA | ARVCF | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
mRNA | LMCD1 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |